西罗莫司涂层球囊治疗慢性肢体威胁性缺血患者股腘动脉病变的前瞻性研究
本研究前瞻性纳入24例慢性肢体威胁性缺血(CLTI)合并股腘动脉病变患者,接受SELUTION SLR西罗莫司涂层球囊(SCB)治疗,平均病变长度152±54.7 mm。手术全部成功,30个月时主要通畅率95.5%、死亡率91.7%、免于大截肢率95.7%,提示SCB在该人群中安全有效,但需长期随访和随机对照试验证实。
要点
- SCB治疗CLTI股腘动脉病变技术成功率高,30个月主要通畅率95.5%。
- 30个月免于大截肢率95.7%,死亡率91.7%,安全性良好。
- 结论需长期随访和随机对照试验进一步验证。
核心结论
- 西罗莫司涂层球囊治疗CLTI患者股腘动脉狭窄闭塞性病变安全有效。
研究设计与样本
- 排除计划初次截肢和股腘动脉长段闭塞(>25 cm)者。
主要发现
- 平均病变长度152±54.7 mm,所有手术均成功。
- 术后3天发生1例早期死亡,源于既存心衰恶化。
- 30个月时主要通畅率95.5%、死亡率91.7%、免于大截肢率95.7%。
关键数值与推荐
- 主要终点为技术成功和主要通畅率,主要通畅定义为双功超声收缩期峰值流速比≤2.4且无再狭窄。
- 次要终点包括死亡、临床驱动的靶病变血运重建、免于再干预和免于大截肢。
临床怎么用
- 对于CLTI合并股腘动脉病变患者,可考虑使用SELUTION SLR西罗莫司涂层球囊作为治疗选择。
- 需注意评估患者心功能,警惕围手术期心血管事件。
局限性
- 样本量小(24例),单中心、非随机设计。
- 随访时间有限,需长期随访和随机对照试验确认结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Angioplasty in chronic limb-threatening ischemia (CLTI) with paclitaxel-coated device has raised doubts on its long-term safety. Consequently, sirolimus-coated balloons (SCBs) have gained more interest given a better safety profile, maintaining good outcomes. This study aims to evaluate the safety and efficacy of SCB (SELUTION SLR; M.A. Med Alliance SA, Nyon, Switzerland) for femoropopliteal arterial disease in patients presenting with CLTI. METHODS: This prospective, single-center study included patients with CLTI with femoropopliteal arterial disease treated between October 2022 and July 2024. Exclusion criteria included planned primary amputation and long-segment occlusions (>25 cm) of the femoropopliteal axis. Primary endpoints were technical success and primary patency (PP). Primary patency was defined as freedom from restenosis determined by a duplex ultrasound peak systolic velocity ratio ≤2.4. Secondary endpoints included mortality, clinically driven target lesion revascularization, freedom from reintervention, and from major amputation. RESULTS: A total of 24 patients were treated during the study period with a mean lesion length of 152 ± 54.7 mm. All procedures were conducted successfully. One early death occurred after 3 days of the index procedure because of worsening of pre-existing cardiac failure. At 30 months, PP, mortality, and freedom from major amputation were 95.5%, 91.7%, and 95.7%, respectively. CONCLUSIONS: These findings suggest that using an SCB is a safe and effective treatment option for femoropopliteal steno-occlusive lesions in CLTI. These results will need to be confirmed by long-term follow-up and randomized controlled trials.Clinical ImpactConcerns about paclitaxel-coated devices have driven the search for safer alternatives. Sirolimus-coated balloons (SCBs) have demonstrated promising results in terms of primary patency and freedom from clinically driven target lesion revascularization. The SELUTION SLR SCB, with its unique drug delivery technology, emerges as a strong candidate in this context. This observational study aims to evaluate its performance in treating femoropopliteal arterial disease in patients with chronic limb-threatening ischemia. Overall, the SELUTION SLR shows encouraging and consistent outcomes in this challenging patient population.
引用
- Bruno S, Mirabella D, Dinoto E, et al. Prospective Sirolimus Coated Angioplasty for Arterial Disease in Patients Presenting Chronic Limb-Threatening Ischemia Study (PROSCAD-CLTI STUDY). J Endovasc Ther. 2026. PMID: 42751879. doi:10.1177/15266028261485137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。